PGRN-RIKEN investigators are releasing the summary data from their published genome-wide association of pharmacogenomics research, in order to enable other researchers to examine particular variants or loci of interest for association with these drug response or adverse response phenotypes. The files include p-values and directions of effect for directly genotyped single nucleotide polymorphisms (SNPs).
Acknowledging the data
When using data from the downloadable results please acknowledge the source of the data as follows: "The GWAS data was contributed by PGRN-RIKEN Investigators and was downloaded from www.pgrn.org/gwas-statistics.html". In addition to the above acknowledgement, please cite the relevant paper.
Download Datasets
1. Allopurinol Response GWAS Summary Statistics
Below is the summary statistics file for allopurinol induced uric acid reduction in 1,495 patients for gout treatment. The sample size and precision of the data presented should preclude de-identification of any individual subject. However, in downloading these data, do not attempt to de-identify individual subjects.
Please cite: Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Wen CC, Yee SW, Liang X, Hoffmann TJ, Kvale MN, Banda Y, Jorgenson E, Schaefer, C, Risch N, Giacomini KM. Clin Pharmacol Ther. 2015 May;97(5):518-25. PubMed: 25676789; PubMed Central: PMC4479153; DOI: 10.1002/cpt.89.
2. Genomewide Association Studies for Cisplatin-Associated Ototoxicity
Below is the summary statistics file for cisplatin-associated ototoxicity in 511 patients. The sample size and precision of the data presented should preclude de-identification of any individual subject. However, in downloading these data, you do not attempt to de-identify individual subjects.
Please cite: Variants in WFS1 and other Mendelian deafness genes are associated with cisplatin-associated ototoxicity. Wheeler HE et al. Clin Cancer Res. 2016 Dec 30 Pubmed: 28039263; DOI: 10.1158/1078-0432.CCR-16-2809
3. Genomewide Association Studies for Anti-Hypertensive Drug Treatment and New-Onset Diabetes
Below is the summary statistics file for anti-hypertensive drug treatment-induced risk for new-onset diabetes in 552 European Americans, 471 Hispanics and 117 African Americans. The sample size and precision of the data presented should preclude de-identification of any individual subject. However, in downloading these data, you do not attempt to de-identify individual subjects
Please cite: Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. Chang SW et al. Pharmacogenomics J. 2016 Sep 27 Pubmed: 27670767; PubMed Central: PMC5368017; DOI: 10.1038/tpj.2016.67
4. Genomewide Association Studies for Colorectal Adenoma Prevention with Celecoxib
Below is the GWAS summary statistics file for colorectal adenoma prevention with celecoxib in 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial. The sample size and precision of the data presented should preclude de-identification of any individual subject. However, in downloading these data, do not attempt to de-identify individual subjects